Related Experiment Video

Updated: Sep 25, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

[Oral antidiabetic therapy and cardiovascular complications: theoretical problem or clinical evidence?]

Gábor Pogátsa1

  • 1Fóvárosi Szent János Kórház, Kardiológiai Szakrendelés, Károlyi Sándor Kórház, Diabetes Szakrendelés, Budapest.

Orvosi Hetilap
|June 11, 2003
PubMed

Insights

Oral antidiabetic drugs significantly impact cardiovascular health in type II diabetes. Choosing the right medication is crucial, especially for patients with existing heart conditions or circulatory issues.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Context:

  • Type II diabetes mellitus management involves various oral antidiabetic drugs.
  • Cardiovascular complications are a major concern for diabetic patients.
  • Different drug classes exhibit varied effects on cardiovascular processes.

Purpose:

  • To analyze the cardiovascular impact of different oral antidiabetic drug classes.
  • To identify drugs that reduce cardiovascular complications.
  • To highlight potential risks associated with specific antidiabetic medications.

Summary:

  • Carbohydrate absorption inhibitors and insulin sensitizers demonstrably reduce diabetic cardiovascular complications.
  • Thiazolidinediones may cause fluid retention, requiring caution in cardiac patients.
  • Some insulin secretagogues (e.g., glibenclamide) inhibit ATP-sensitive potassium channels, reducing vasodilation and ischemic preconditioning.

Impact:

  • The choice of antidiabetic medication is critical for patients with ischemic heart disease or peripheral arterial disease.
  • Insulin therapy may be necessary for managing severe ischemic alterations or secondary sulfonylurea resistance.
  • Optimizing drug selection can prevent further cardiovascular complications in diabetic individuals.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Complications of Diabetes Mellitus01:22

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...